Barclays’s Mateon Therapeutics, Inc. MATN Stock Holding History

Barclays’s Portfolio MATN Stock Details MATN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-105	Closed	–	–	7058
2016 Q3	$0	Hold	105	–	–	﹤0.01%	6987
2016 Q2	$0	Buy	+105	New	+$74	﹤0.01%	6893

Other funds holding MATN

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Barclays's MATN Position: Q4 2016 in Review

Barclays sold out of Mateon Therapeutics, Inc. (MATN) in Q4 2016, closing a stake of 105 shares.

Barclays first reported a position in MATN in Q2 2016 and held it in 2 quarters. The position peaked at $0 in Q3 2016. 1 fund tracked by Wall St. Rank holds MATN as of Q4 2016.

Barclays reported no remaining Mateon Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Barclays sold 105 Mateon Therapeutics, Inc. shares in Q4 2016.
Barclays first reported a position in Mateon Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
Barclays's Mateon Therapeutics, Inc. position peaked at $0 in Q3 2016.
1 fund tracked by Wall St. Rank held Mateon Therapeutics, Inc. as of Q4 2016.

Based on Barclays's 13F filing for Q4 2016, filed 14 Feb 2017.